Article Details

Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

Retrieved on: 2021-05-19 22:18:45

Tags for this article:

Click the tags to see associated articles and topics

Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting. View article details on hiswai:

Excerpt

New data analyses from the Phase 3 ARIEL3 and ARIEL4 trials further characterize Rubraca's efficacy and consistent safety profile in patients in the ...

Article found on: finance.yahoo.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up